Assessment of coronary artery bypass grafts by magnetic resonance imaging.

This study evaluated graft patency and flow at rest/stress in patients with coronary artery bypass grafts using MR flow measurements and MR angiography (MRA). 45 symptomatic patients with 86 grafts (46 arterial, 40 venous) were examined 5.5 years after surgery. MRA was used to assess bypass patency. Flow measurements were performed at rest and after stress induction with dipyridamole. All graft segments were evaluated at MRA for stenosis, and were additionally evaluated by the combination of flow measurements and MRA. Conventional coronary angiography or multidetector computed tomography was regarded as a reference standard. No significant stenosis was observed in 49 grafts (Group A), whereas significant stenosis was observed in 37 grafts (Group B). Sensitivity, specificity, and positive and negative predictive values for stenosis in arterial grafts were 95.2%, 96.8%, 80% and 99.4%, respectively, and in venous grafts were 100%, 97.8%, 87.5% and 100%, respectively. The mean blood flow rate at baseline/stress in Group B was significantly lower than that in Group A (p<0.002/p<0.001). With the combined MR method, 84 of 86 (97%) grafts could be correctly classified. In conclusion, MRI allows a combined assessment of graft status, including bypass patency and flow, in symptomatic patients after revascularization.

[MR angiography and determination of the flow reserve after minimal invasive direct coronary artery bypass (MIDCAB) surgery of the left internal mammary artery in comparison to multirow CT]. / MR-Angiographie und Flussreservenbestimmung nach minimalinvasiver direkter Koronararterien-Bypass(MIDCAB)-Operation der linken Arteria mammaria interna im Vergleich zur Mehrzeilen-CT.

PURPOSE: To evaluate graft patency, flow and flow reserve in patients with minimal invasive direct coronary artery bypass (MIDCAB) of internal mammary artery (IMA) grafts using a combined MR protocol with phase-contrast technique and MR angiography. MATERIAL AND METHODS: At a 1.5T Magnetom Sonata (SIEMENS), 19 symptomatic (angina CCS I-III, intermittent thoracic discomfort, scar disorders) patients (59.9 +/- 7.9 years old) with 19 left internal mammary artery (LIMA) grafts implanted in minimal invasive technique were examined 6.9 +/- 1.5 years post surgery. Contrast enhanced MR angiography (TR 2.5 ms, TE 1 ms, flip angle 20 (o), spatial resolution 1.4 x 0.9 x 1.0 mm(3), breath hold technique, no ECG-triggering, 25 ml Gd-DTPA) was performed to assess bypass patency. Phase-contrast flow measurements with retrospective gating (TR 41 msec, TE 3.2 msec, flip angle 30 degrees , spatial resolution 1.1 x 1.1 x 5 mm(3), temporal resolution 42 msec, venc 90 cm/sec) were applied in the IMA grafts at rest and after stress induction with dipyridamole (0.56 mg/kg/BW). For comparison, graft patency was evaluated by multidetector-row computed tomography (16-row CT). In 9 patients a selective catheter angiography was performed. RESULTS: MIDCAB grafts were occluded in 4/19 patients. In 4 patients the anastomosis to LAD was highly stenotic (> 70 %) at MDCT (2 experienced investigators in consensus reading). In MRA 9 grafts could be delineated completely including the distal anastomosis to LAD (47 %). In 9 patients the distal part could not be evaluated. In patients with patent grafts (MDCT), a significant improvement of graft flow (at rest 75.4 +/- 33.3 ml/min; after stress 202.7 +/- 49.6; P < 0.002) and flow reserve (patent grafts 3.0 +/- 1.1; stenotic grafts 1.5 +/- 0.2, P < 0.02; occluded grafts 0.9 +/- 0.2, P < 0.01) after stress induction was detected. Diastolic-to-systolic peak velocity ratios (D/S-PVR) at baseline were not significant between patent and stenotic grafts. Mean flow at baseline and after stress induction and flow reserve show a high sensitivity (91/92 /83 %) and specificity (86 /100/83 %) for detection of graft stenosis. MR angiography combined with flow reserve measurements could distinguish between occluded/stenotic and patent grafts in all MIDCAB grafts. CONCLUSION: MR imaging allows combined assessment of bypass patency and flow with flow reserve in patients after MIDCAB. The protocol of this study is applicable for the evaluation of graft patency in patients after revascularization.

Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research.

PURPOSE: The aim of this review is to present the current state of clinical oncological research on mistletoe extracts standardised in terms of the active substance mistletoe lectin. METHODS: This review focuses on studies with clearly defined mistletoe extracts standardised in terms of mistletoe lectins I, II, and III (calculated as mistletoe lectin I, ML I) which belong to the category of rational phytotherapy. That means that studies with anthroposophic or homeopathic drugs will not be included. RESULTS: There are several preclinical studies that show a cytotoxic and immunostimulating effect of mistletoe extracts, predominantly on the cellular immune system. The clinical database, however, is not as good as the experimental results. So far, no direct anticancer action or any improvement in time to tumour progression or overall survival in cancer patients has been seen. The first results of a randomised phase III study suggest that additive administration of a mistletoe preparation may improve the quality of life. CONCLUSION: Mistletoe therapy has not gained an established place in oncology. Further, well-planned randomised clinical investigations will be necessary to verify the first positive findings with regard to an improvement of quality of life in cancer patients.